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INTRODUCTION
Postoperative hyponatremia is relatively common among 
postoperative complications that occur in patients who under-
went transsphenoidal surgery (TSS) for pituitary adenomas, 
with incidence varying from 1.8% to 35% [1-6]. Common clin-
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Background    Hyponatremia is a common complication after transsphenoidal surgery (TSS) for pitu-
itary adenomas. This study retrospectively reviewed various clinical factors of pituitary adenoma pa-
tients who underwent TSS and aimed to identify possible risk factors of postoperative hyponatremia.
Methods    Total 1,343 patients who underwent TSS for their pituitary adenomas in a single insti-
tution were enrolled to this study. We identified and analyzed 93 patients (6.9%) with postoperative hy-
ponatremia and compared them with other 1,250 patients in a control group. Patients’ age, sex, tumor 
extent based on the modified Hardy classification, tumor size and hormonal type of the tumors were 
analyzed in comparison between two groups. The results of pre- and post-operative combined pituitary 
function test and their comparison were analyzed to elucidate a possible association between postop-
erative hyponatremia and hypopituitarism.
Results    The onset of postoperative hyponatremia was 7.8 days after surgery (range: postop-
erative day 3-13). The initial level of serum sodium (Na) level at the start of treatment was 123.5 mmol/L 
(range: 114-131 mmol/L) and the duration of treatment was 2.7 days (range: 1-9 days). Female pre-
dominance was evident in the hyponatremia group (77.4% vs. 61.4%, p=0.02). Preoperative hypopitu-
itarism (58.5% vs. 71.5%, p=0.007) and postoperative hypocortisolism (33.7% vs. 23.4%, p=0.029) 
were related to postoperative hyponatremia. Other pre- and post-operative clinical factors were not 
associated with postoperative hyponatremia.
Conclusion    Postoperative hyponatremia is a common complication after TSS and is potentially 
fatal. Female patients were more likely to develop delayed hyponatremia. We demonstrated possible 
associations of delayed postoperative hyponatremia with preoperative and postoperative pituitary 
functions, but the mechanism behind it should be further investigated.
Key Words  Hyponatremia; Hypopituitarism; Pituitary neoplasms; Postoperative complications.
ical presentations include headaches, nausea and vomiting, but 
more severe symptoms like seizures, mental change can devel-
op if left untreated. It is known that significant postoperative 
hyponatremia usually develops after the latter part of first post-
operative week, however, its pathophysiology has been under 
debate [5,7-9]. Hormonal imbalance caused by disruption of 
the normal pituitary gland during surgery is thought to be the 
mechanism behind it, but the exact mechanism or risk factors 
of postoperative hyponatremia is still unclear despite several 
previous studies [1,3,4,6,10-13]. As the consequences of un-
treated hyponatremia are often fatal, this study aims to ascer-
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tain risk factors associated with postoperative hyponatremia 
in patients who underwent TSS for their pituitary adenomas.
MATERIALS AND METHODS
Patient population
Total 1,343 patients with pituitary adenomas operated with 
TSS in our institution were included in this study. Patients’ 
medical record and imaging studies were retrospectively re-
viewed. This study was conducted in accordance with the Dec-
laration of Helsinki and approved by Institutional Review Board 
in our institute (4-2018-0039), waving the patient’s written con-
sent as a retrospective study. Delayed hyponatremia was de-
fined as sodium level less than 135 mmol/L that occurred on 
or after postoperative day 3. We identified 93 patients who pre-
sented with rapid drop of their sodium level or significant clini-
cally relevant symptoms, and thus required administration of 
hypertonic saline (3% NaCl). These 93 patients were defined 
as hyponatremia group and their clinical features were com-
pared with those of control group.
Patient evaluation
All patients were evaluated preoperatively with dynamic 
sellar MRI using either 1.5-Tesla system (Signa, General Elec-
tric, Minneapolis, MN, USA) or 3.0-Tesla system (Achieva, 
Philips, Best, The Netherlands). Tumor size was determined 
as a maximum diameter of the tumor on a coronal view of 
preoperative MRI. With the preoperative MRI all the patients 
were classified into modified Hardy’s classification of pitu-
itary adenoma [14-16]. Immediate postoperative 3-Tesla MRI 
was performed 48 hours after the surgery to determine the 
radicality of tumor removal. Specific methods of endocrino-
logical assessment were fully described in our previous re-
port [13]. Combined pituitary function test (CPFT) was per-
formed to evaluate anterior pituitary function before surgery, 
6–12 months after surgery and every 2 years thereafter.
Surgical procedure
All tumors were approached by conventional microscopic 
or endoscopic transsphenoidal approach. After dural opening, 
identification of normal anatomy and evaluation of tumor 
and the surrounding pseudocapsule was done. If the tumor 
was hard or surrounded by a thick pseudocapsule, dissection 
was performed along the outer margin of the pseudocapsule. 
If the tumor was fragile and soft enough, it was removed in a 
piecemeal fashion. Pseudocapsule was removed in all possible 
circumstances to prevent recurrence. Hormonal type of pitu-
itary adenoma was confirmed with microscopic examination 
of specimen with immunohistochemistry of relevant pituitary 
hormones by a proficient pathologist.
Statistical analysis
Student’s t-test was performed to evaluate the difference of 
average age and tumor size between the hyponatremia group 
and control. Chi-squared test was performed to evaluate the 
difference of distribution regarding sex, Hardy classification, 
hormonal type, preoperative hypopituitarism, tumor removal 
radicality, tumor removal fashion and hormonal outcome. In 
all statistical analyses, p-value of <0.05 was considered signif-
icant. Statistical analyses were performed using SPSS statisti-
cal software (version 15.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Out of total 1,343 pituitary adenoma patients, we identified 
93 patients (6.9%) with postoperative hyponatremia that re-
quired hypertonic saline infusion. Our routine daily laborato-
ry evaluation includes water intake/output, serum electrolytes 
(sodium, potassium, chloride), urine specific gravity. Once hy-
ponatremia was detected, 3% NaCl infusion was started imme-
diately when the sodium level was below 130 mmol/L or pa-
tient showed significant relevant symptoms. Four hours after 
initiation of hypertonic saline, serum electrolyte levels were 
followed up and infusion rate was adjusted, which were repeat-
ed until we stabilized hyponatremia. For correction rate of hy-
ponatremia, we stuck to the consensus guidelines [17,18]. The 
initiation of hypertonic saline infusion, which can be consid-
ered as onset of hyponatremia, was 7.8 days after surgery (range: 
postoperative day 3–13) (Fig. 1). Initial mean serum sodium 
level right before starting hypertonic saline infusion was 124.3± 
4.8 mmol/L, ranging from 111 to 132 mmol/L. Patients required 
average 2.7 days (range: 1–9) of hypertonic saline infusion be-
fore resolution of symptoms and sustained recovery of serum 
sodium level.
Preoperative characteristics
Preoperative characteristics of 93 patients with postopera-
tive hyponatremia are summarized in Table 1. The group in-
cluded 21 males and 72 females with a mean age of 44.7 (range: 
19–75) at the time of surgery. The proportion of female patients 
were significantly higher in the hyponatremia group compared 
to control (77.4% vs. 61.4%, p=0.02). The mean preoperative 
size of tumor was 19.7 mm (range: 5–55). We witnessed no sig-
nificant difference in age (44.7 vs. 43.1, p=0.245) and tumor size 
(19.7 vs. 19.3, p=0.692). Patients were classified into modified 
Hardy’s classification, resulting in 31 patients (33.3%) of type I, 
15 patients (16.1%) of type II, 31 patients (33.3%) of type III 
and 16 patients (17.2%) of type IV. Regarding hormonal sub-
types, nonfunctioning adenoma was the most common, num-
bering up to 41 patients (44.1%), followed by growth hormone-
secreting (33 patients, 35.5%), prolactin-secreting (11 patients, 
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11.8%) and adrenocorticotropin-secreting subtype (8 patients, 
8.6%). There was no significant difference of distribution re-
garding modified Hardy’s classification, hormonal subtypes of 
adenomas. Among 1,299 patients who underwent preopera-
tive CPFT, total 917 patients presented with preoperative hy-
popituitarism in at least one of their pituitary hormone axes. 
The incidence of preoperative hypopituitarism was lower in a 
hyponatremia group than in a control group (58.5% vs. 71.5%, 
p=0.007). However, the incidence of adrenocorticotropic hor-
mone (ACTH) axis hypofunction was similar in both groups.
Postoperative outcomes
Postoperative outcomes are summarized in Table 2. Total 
resection was achieved in 83 patients (89.2%) of hyponatre-
mia group. Tumors were removed in piecemeal fashion in 55 
patients (59.1%) and in capsulectomy fashion in 38 patients 
(40.9%). There was no significant difference in total resection 
rate (89.2% vs. 87.8%, p=0.712) or capsulectomy rate (59.1% 
vs. 64.2%, p=0.328) between the two groups. 
44 patients from hyponatremia group and 582 patients from 
control group (49.4% vs. 48.0%, p=0.796) showed postopera-
tive hypopituitarism in at least one axis of anterior pituitary 
function. Incidence of pituitary function deterioration after 
surgery was evaluated with direct comparison of preopera-
tive and postoperative CPFT, and no difference was found be-
tween the two groups (10.6% vs. 6.9%, p=0.203). On the con-
trary, decreased pituitary function in ACTH axis showed strong 
association with the presence of postoperative hyponatremia 
(33.7% vs. 23.4%, p=0.029). 
DISCUSSION
Patients with hyponatremia present a variety of symptoms 
from simple headaches, muscle cramps to more severe symp-
toms like seizures, mental change, respiratory arrest [19]. Se-
vere symptomatic hyponatremia should be managed imme-
diately as delayed treatment can lead to fatal results. Although 
hyponatremia is a common postoperative complication of TSS, 
little is known about its time course and risk factors. The ex-
act mechanism behind postoperative hyponatremia is still un-
known; theories suggest excessive antidiuretic hormone (ADH) 
secretion after surgery induced by vagal stimuli (headache, stress, 
nausea) or immediate release of ADH into vascular space due 
to surgical exploration as possible mechanisms. Previous stud-
ies suggested old age [13], female sex [6], Cushing’s disease 
[10,20], tumor size [11], presence of transient diabetes insipi-
dus as risk factors of postoperative hyponatremia. It is also re-
ported that significant hyponatremia does not occur until the 
latter part of 1st postoperative week to early 2nd week [5,7-9].
This study retrospectively reviewed data of 1,343 pituitary 
adenoma patients, of which 93 patients (6.9%) presented with 
postoperative hyponatremia. The incidence, onset time, and 
duration of postoperative hyponatremia presented in this study 
are consistent with previous reports. Various preoperative and 
postoperative characteristics were analyzed to identify any pos-
sible risk factor of hyponatremia. Although old age is a frequent-
ly reported risk factor for postoperative hyponatremia, there 
was no significant difference of average age between the hy-
ponatremia group and the control group in this study. There 
was significant sex predilection towards female in hyponatre-
mia group compared to control, which was also witnessed by 



















































Fig. 1. Characteristics of hyponatremia patients. A: Initial serum sodium level right at the onset of postoperative hyponatremia is 124.3± 
4.8 mmol/L. B: Onset of delayed hyponatremia is 7.8 days after surgery. C: Hypertonic saline infusion is administrated for 2.7 days.
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postoperative hyponatremia. Factors related to higher risk of 
normal gland violation, such as bigger tumor size or suprasellar 
extension, was not associated with postoperative hyponatre-
mia. As hyponatremia frequently associates with hypocorti-
solism [21], we speculated that the incidence of ACTH dys-
function would be higher in a hyponatremia group than in a 
control group, we failed to demonstrate a statistically signifi-
cant difference in the incidence of preoperative ACTH dys-
function between two groups. It was an interesting finding that 
the incidence of hypopituitarism was lower in a hyponatremia 
group, which may suggest this complication may more fre-
quently associates with patients with relatively well preserved 
pituitary functional capacity.
There was no difference in total removal rate or capsulecto-
my rate between the hyponatremia group and the control group. 
Postoperative hypopituitarism was not associated with post-
operative hyponatremia, but postoperative ACTH dysfunction 
was strongly related to hyponatremia suggesting ACTH dys-
function may be the leading cause of hyponatremia.
Mechanism of postoperative hyponatremia in pituitary ad-
enoma patients is still unclear. Some previous studies suggest-
ed that increased level of ADH after surgery may be a possible 
cause of postoperative hyponatremia [7,22,23]. Unregulated 
ADH release from surgically manipulated posterior pituitary 
gland occurs few days after surgery, resulting in fluid retention 
and natriuresis [10]. This theory is in good agreement with the 
delayed onset of hyponatremia [7,23]. On the contrary, other 
studies have also reported cases of hyponatremia in the set-
tings of normal or low level of ADH [9,24-26]. In this case, hy-
ponatremia is explained by actions of atrial natriuretic hor-
mones and brain natriuretic hormone resulting in excessive 
natriuresis rather than fluid retention, also known as cerebral 
salt wasting syndrome. As aforementioned, another possible 
mechanism for delayed hyponatremia is secondary adreno-
cortical insufficiency [9,27]. Although the present study showed 
no correlation between hormonal type of pituitary adenoma 
and postoperative hyponatremia, some previous studies have 
reported higher risks of hyponatremia after TSS in Cushing 
patients compared to prolactinoma by 3 folds, or non-function-
ing adenomas by 2.8 folds [24]. This study showed that post-
operative adrenal insufficiency can be a risk factor for delayed 
hyponatremia. It should be further investigated whether ade-
quate cortisol replacement could prevent development of post-
operative hyponatremia.
This study defined hyponatremia group as patients with post-
Table 2. Postoperative outcomes of the patients
Patients with postoperative 
hyponatremia (%)
Patients without postoperative 
hyponatremia (%)
p-value
Total resection number/total number of the patients* 83/93 (89.2) 1,096/1,246 (87.8) 0.712
Tumor removal fashion (piecemeal:capsulectomy)* 55:38 796:444 0.328
Postoperative hypopituitarism/total patients evaluated by CPFT† 44/89 (49.4) 582/1,212 (48.0) 0.796
Subnormal response in ACTH axis/total patients evaluated by CPFT† 30/89 (33.7) 284/1,212 (23.4) 0.029‡
Worsened pituitary function/total patients evaluated by CPFT† 9/85 (10.6) 80/1,159 (6.9) 0.203
*Number of patients after excluding any patients with missing data, †Number of patients who were evaluated by combined pituitary function 
test for their pituitary function, ‡p<0.05. ACTH, adrenocorticotropin hormone; CPFT, combined pituitary function test








Number of patients 93 1,250
Age (year) 44.7 43.1 0.692
Sex (male:female) 21:72 482: 768 0.002†
Hardy classification (%) 0.199
I 31 (33.3) 298 (23.8)
II 15 (16.1) 234 (18.7)
III 31 (33.3) 437 (35.0)
IV 16 (17.2) 281 (22.5)
Tumor size (mm) 19.71±11.54 19.29±9.96 0.245
Hormonal type (%) 0.490
NFT 41 (44.1) 592 (47.4)
GH 33 (35.5) 388 (31.0)
PRL 11 (11.8) 150 (12.0)
ACTH 8 (8.6) 88 (7.0)
TSH 0 (0.0) 32 (2.6)
Hormonal activity  




   hypopituitarism/total 
patients evaluated by 
CPFT*
55/94 (58.5) 862/1,205 (71.5) 0.007†
Subnormal response  
   in ACTH axis/total 
patients evaluated by 
CPFT*
22/90 (24.4) 325/1,209 (26.9) 0.614
*Patients without preoperative CPFT were excluded, †p<0.05. 
ACTH, adrenocorticotropin hormone; CPFT, combined pituitary 
function test; GH, growth hormone; NFT, non-functioning tu-
mor; PRL, prolactin; TSH, thyroid stimulating hormone
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operative hyponatremia with symptoms severe enough to need 
hypertonic saline infusion. Overall incidence of hyponatremia 
might have been underrated compared to previous studies. We 
were not able to provide a reasonable explanation for the fe-
male predilection reported in hyponatremia group. Although 
some of the previous studies have reported the same, none had 
success in providing a meaningful discussion. This study did 
not include any analysis regarding the mechanism of hypona-
tremia such as serum ADH level or urine sodium level. The 
hyponatremia group we set might be heterogeneous, including 
different types of hyponatremia. The primary endpoint of this 
study was to seek for any clinical factor relevant to postoper-
ative hyponatremia. Further study regarding the mechanism 
behind postoperative hyponatremia needs to be done.
In conclusion, postoperative hyponatremia is a common 
complication after TSS. Recognition of its risk factors is essen-
tial since delayed detection or treatment can lead to critical 
results. While tumor size, modified Hardy classification and 
tumor removal radicality were not associated with delayed hy-
ponatremia, we demonstrated delayed postoperative hypo-
natremia was more prevalent in female and patients with peri-
operative pituitary dysfunction, rendering them as possible 
risk factors.
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